RETATRUTIDE 10MG
Previously produced weight loss preparations affect GLP-1 and GIP receptors - responsible for inhibiting appetite.
Retatrutide has a "THREE-way" effect. - on the given receptors and on the THIRD - the glucagon receptor, thus regulating also lipid and glucose metabolism.
The Triple G effect of Triple G makes it more effective than other formulations.
Retatrutide is a state-of-the-art peptide. Retatrutide is an agonist of three receptors ( GLP-1, GIP and Glucagon), not as in the case of Semaglutide (GLP-1) and Thiothiopathid (GLP-1, GIP). The latest study shows that patients treated with Triple G were able to lose as much as 24.2% of their total body weight. This is the best result to date among other substances with similar effects.
All relatively new weight-loss formulations work by mimicking hormones in the body that regulate hunger and satiety. Ozempic(Semaglutide) is designed to act like one of these hormones, known as glucagon-like peptide 1(GLP-1). Mounjaro(Thirzepatide) acts like both GLP-1 and another hormone called GIP. Triple G acts like GLP-1, GIP and a third hormone known as glucagon, which is also involved in regulating hunger.
According to results from a mid-stage clinical trial presented at the American Diabetes Association's annual meeting in San Diego and published in the New England Journal of Medicine (NEJM) on June 26, the injectable drug, Triple G, helped obese people lose up to 24 percent of their body weight on average.
"What's striking is that, on average, obese participants taking the highest dose of Triple G lost nearly a quarter of their body weight," said the study's lead author, Dr. Ania Jastreboff, associate professor and director of the weight management center at the Yale School of Medicine in New Haven, Connecticut, in a press release.
https://www.nejm.org/doi/10.1056/NEJMoa2301972
In the Triple G study published in NEJM, researchers randomly assigned 338 adults with obesity to take either placebo or one of four different doses of Triple G: 1 milligram (mg), 4 mg, 8 mg or 12 mg. Each patient taking the highest dose of Triple G lost at least 5 percent of their body weight after 48 weeks of treatment; about 1 in 4 lost at least 30 percent of their body weight.
PRODUCT INTENDED FOR RESEARCH PURPOSES!
Additional informations:
- The product (substance) isn't a food or diet supplement and is not suitable for human consumption.
- Keep out of children's reach
- Keep container tightly closed.
- Store in a dry, cool and shaded place; protect from moisture.
- Store only in the original container.
- Avoid contact during pregnancy and breast feeding.
- Consult a doctor in the event of feeling unwell or having adverse effects related to the contact with the substance.